Clinical trial(s) targeting cell cycle checkpoints
| Trial | Phase | Notable Common Grade AEs (≥10%) | Drugs | Results | Time | Reference |
|---|---|---|---|---|---|---|
| DUETTE NCT04239014 | Randomized, double-blinded, placebo-controlled phase II | N/A | Ceralasertib + olaparib | No publications available | 2020 | DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment |